Souhaitez-vous accéder aux communiqués récents ?

SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it...

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and...

Delray Beach, FL, March 16, 2026 (GLOBE NEWSWIRE) -- The global cell culture market, valued at USD 27.92 billion in 2024, stood at USD 29.76 billion in 2025 and is projected to advance at a...

- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted...

- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - -...

Junshi Biosciences announced its financial results for the full year of 2025 and provided corporate updates.

Highlights strategic progress achieved under Abizer Gaslightwala’s leadership, including advancement of AKTX-101 and expansion of Akari’s ADC pipeline  Access the Akari CEO Corner here TAMPA, Fla....

Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Tivdak Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...

First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025...

BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on...